{
    "hands_on_practices": [
        {
            "introduction": "The biomedical model often defines health and illness through measurable, physiological parameters. This first practice provides a foundational skill in this quantitative approach: operationalizing pathology as a statistically significant deviation from a population norm. By calculating a standardized score, or $z$-score, you will learn how to translate a raw measurement into a universal metric of clinical significance, a cornerstone of laboratory medicine and quantitative assessment .",
            "id": "4750335",
            "problem": "In the biomedical model of health and illness, pathology is often operationalized as biological deviation from a population-defined norm. Suppose a laboratory parameter used in a medically oriented psychological assessment is well-approximated by a Gaussian (normal) distribution in a reference healthy adult population with population mean $\\mu = 100$ (in the parameter’s native units) and population Standard Deviation (SD) $\\sigma = 20$. A patient presents with a measured value $x = 150$. A clinic following a strictly biomedical decision rule classifies a case as potentially pathological when the magnitude of its standardized deviation from the reference mean is at least $2$, that is when $|z| \\geq 2$.\n\nUsing only foundational statistical definitions (population mean, population Standard Deviation (SD), and the linear standardization of a normal variable to a unit-variance reference), derive from first principles the standardized deviation $z$ for this patient’s measurement and determine, in your reasoning, whether the biomedical rule would flag pathology for this case.\n\nProvide only the standardized value $z$ as your final answer, reported as a pure number with no units. No rounding is required; if you choose to round, report $z$ to $3$ significant figures.",
            "solution": "The problem is first validated for scientific and logical integrity. The givens are:\n1.  A laboratory parameter follows a Gaussian (normal) distribution.\n2.  Population mean, $\\mu = 100$.\n3.  Population Standard Deviation (SD), $\\sigma = 20$.\n4.  A patient's measured value, $x = 150$.\n5.  A decision rule for flagging pathology: the magnitude of the standardized deviation, $|z|$, must be greater than or equal to $2$, i.e., $|z| \\geq 2$.\n\nThe problem is valid. It is scientifically grounded in fundamental statistical principles (the normal distribution, mean, standard deviation, and z-score) that are central to biostatistics and quantitative assessment in medicine. The problem is well-posed, providing all necessary data ($\\mu$, $\\sigma$, $x$) to calculate the requested value ($z$). The language is objective and the values are physically plausible. The task is to derive the standardized deviation from first principles and apply a decision rule, which is a standard and verifiable procedure.\n\nWe now proceed with the solution.\n\nThe core principle is the standardization of a variable. Standardization transforms a variable from its native units into a universal scale of \"standard deviations from the mean\". This allows for the comparison of values from different distributions. Let the random variable for the laboratory parameter be denoted by $X$. We are given that $X$ is normally distributed with mean $\\mu$ and standard deviation $\\sigma$. A specific observation of this variable is $x$.\n\nThe first principle of standardization is to measure the deviation of an observation from the population mean. This deviation is given by the difference:\n$$\n\\text{Deviation} = x - \\mu\n$$\nFor the given patient, this deviation is:\n$$\nx - \\mu = 150 - 100 = 50\n$$\nThis value of $50$ is in the parameter's native units. To make it a standardized, unitless measure, we must express this deviation relative to the characteristic spread of the population. The standard unit of spread in the population is the standard deviation, $\\sigma$.\n\nThe standardized deviation, or $z$-score, is therefore defined as the ratio of the deviation from the mean to the standard deviation. This represents the number of standard deviations the observation $x$ is away from the mean $\\mu$. The formula derived from this principle is:\n$$\nz = \\frac{x - \\mu}{\\sigma}\n$$\nWe are given the following values:\n- Patient's measurement: $x = 150$\n- Population mean: $\\mu = 100$\n- Population standard deviation: $\\sigma = 20$\n\nSubstituting these values into the derived formula:\n$$\nz = \\frac{150 - 100}{20}\n$$\n$$\nz = \\frac{50}{20}\n$$\n$$\nz = 2.5\n$$\nThe standardized deviation for this patient's measurement is $z = 2.5$.\n\nThe problem also requires us to determine if the biomedical rule would flag pathology. The decision rule is to flag a case if $|z| \\geq 2$. For this patient, we have:\n$$\n|z| = |2.5| = 2.5\n$$\nWe then check if this value satisfies the condition:\n$$\n2.5 \\geq 2\n$$\nThis inequality is true. Therefore, according to the strictly biomedical decision rule specified, this patient's case would be flagged as potentially pathological because the measured value is $2.5$ standard deviations above the population mean, which exceeds the threshold of $2$ standard deviations. The final answer required is the value of $z$ itself.",
            "answer": "$$\\boxed{2.5}$$"
        },
        {
            "introduction": "While identifying a deviation is a key first step, interpreting the result of a diagnostic test requires a deeper understanding of probability. Tests are not perfect, and their predictive power depends heavily on the context of the population being tested. This exercise will guide you through the derivation and application of Bayes' theorem to calculate the Positive Predictive Value (PPV), revealing the crucial interplay between a test's sensitivity, specificity, and the disease's prevalence in a population . Mastering this concept is essential for accurately interpreting diagnostic evidence and avoiding common clinical reasoning errors.",
            "id": "4750313",
            "problem": "A screening test for a single disease is used within the biomedical model of health and illness to identify a biological disease state rather than psychosocial factors. Let the test property of sensitivity be defined as $\\Pr(T^{+}\\mid D)$, where $T^{+}$ denotes a positive test and $D$ denotes having the disease, and let the test property of specificity be defined as $\\Pr(T^{-}\\mid \\neg D)$, where $T^{-}$ denotes a negative test and $\\neg D$ denotes not having the disease. Let the population prevalence be $\\Pr(D)$. The positive predictive value (PPV) is the probability that an individual truly has the disease given a positive test, $\\Pr(D\\mid T^{+})$.\n\nStarting from the fundamental probabilistic definitions above and the law of total probability together with Bayes theorem, derive an expression for the positive predictive value $\\Pr(D\\mid T^{+})$ in terms of sensitivity, specificity, and prevalence, then evaluate it numerically for sensitivity $=0.90$, specificity $=0.95$, and prevalence $=0.10$. Finally, briefly interpret what this value means clinically within the biomedical model, focusing on the implications for decision-making and patient communication.\n\nExpress the numerical PPV as a decimal rounded to four significant figures. Do not use a percentage sign.",
            "solution": "The problem requires the derivation of an expression for the Positive Predictive Value (PPV) of a medical screening test, a numerical evaluation of this expression for given parameters, and a clinical interpretation of the result. The validation of the problem statement is the mandatory first step.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n- Sensitivity, $\\text{sens} = \\Pr(T^{+}\\mid D)$, where $T^{+}$ is a positive test and $D$ is having the disease.\n- Specificity, $\\text{spec} = \\Pr(T^{-}\\mid \\neg D)$, where $T^{-}$ is a negative test and $\\neg D$ is not having the disease.\n- Prevalence, $\\text{prev} = \\Pr(D)$.\n- Positive Predictive Value, $\\text{PPV} = \\Pr(D\\mid T^{+})$.\n- Numerical values for evaluation: sensitivity $=0.90$, specificity $=0.95$, prevalence $=0.10$.\n- Required tasks:\n    1. Derive an expression for $\\text{PPV}$ in terms of sensitivity, specificity, and prevalence.\n    2. Evaluate the numerical value of $\\text{PPV}$ rounded to four significant figures.\n    3. Provide a brief clinical interpretation.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded, well-posed, and objective. It is a standard application of probability theory, specifically Bayes' theorem, to the field of medical diagnostics and epidemiology. The definitions of sensitivity, specificity, prevalence, and PPV are standard and correctly stated. The context of the biomedical model is appropriate, as these metrics are used to quantify the performance of a test in identifying a biological disease state. The provided numerical values are realistic for a screening test. The problem is self-contained, with all necessary information provided for a unique solution. There are no contradictions, ambiguities, or logical flaws.\n\n**Step 3: Verdict and Action**\nThe problem is deemed valid. A full solution will be provided.\n\n### Derivation of the Positive Predictive Value\n\nThe Positive Predictive Value, $\\text{PPV}$, is defined as the conditional probability $\\Pr(D\\mid T^{+})$. We begin with the definition of conditional probability, which can be rearranged to form Bayes' theorem:\n$$\n\\Pr(D\\mid T^{+}) = \\frac{\\Pr(T^{+}\\mid D)\\Pr(D)}{\\Pr(T^{+})}\n$$\nThe terms in the numerator are given directly by the problem statement:\n- $\\Pr(T^{+}\\mid D)$ is the sensitivity, $\\text{sens}$.\n- $\\Pr(D)$ is the prevalence, $\\text{prev}$.\n\nThe term in the denominator, $\\Pr(T^{+})$, is the total probability of obtaining a positive test result. This can be expanded using the law of total probability by conditioning on the disease state (either the individual has the disease, $D$, or does not, $\\neg D$).\n$$\n\\Pr(T^{+}) = \\Pr(T^{+}\\mid D)\\Pr(D) + \\Pr(T^{+}\\mid \\neg D)\\Pr(\\neg D)\n$$\nWe can identify the components of this expansion:\n- $\\Pr(T^{+}\\mid D) = \\text{sens}$\n- $\\Pr(D) = \\text{prev}$\n- $\\Pr(\\neg D)$ is the probability of not having the disease, which is $1 - \\Pr(D) = 1 - \\text{prev}$.\n- $\\Pr(T^{+}\\mid \\neg D)$ is the probability of a positive test given the absence of disease. This is the false positive rate. It can be derived from the specificity, $\\text{spec} = \\Pr(T^{-}\\mid \\neg D)$. Since for a non-diseased individual the test can only be positive or negative, we have $\\Pr(T^{+}\\mid \\neg D) + \\Pr(T^{-}\\mid \\neg D) = 1$. Therefore, $\\Pr(T^{+}\\mid \\neg D) = 1 - \\Pr(T^{-}\\mid \\neg D) = 1 - \\text{spec}$.\n\nSubstituting these expressions into the expansion for $\\Pr(T^{+})$ yields:\n$$\n\\Pr(T^{+}) = (\\text{sens})(\\text{prev}) + (1 - \\text{spec})(1 - \\text{prev})\n$$\nFinally, substituting all the component expressions back into the formula for $\\text{PPV}$ gives the desired expression:\n$$\n\\text{PPV} = \\Pr(D\\mid T^{+}) = \\frac{(\\text{sens})(\\text{prev})}{(\\text{sens})(\\text{prev}) + (1 - \\text{spec})(1 - \\text{prev})}\n$$\n\n### Numerical Evaluation\n\nWe are given the following values:\n- $\\text{sens} = 0.90$\n- $\\text{spec} = 0.95$\n- $\\text{prev} = 0.10$\n\nSubstituting these values into the derived formula:\n$$\n\\text{PPV} = \\frac{(0.90)(0.10)}{(0.90)(0.10) + (1 - 0.95)(1 - 0.10)}\n$$\n$$\n\\text{PPV} = \\frac{0.09}{0.09 + (0.05)(0.90)}\n$$\n$$\n\\text{PPV} = \\frac{0.09}{0.09 + 0.045}\n$$\n$$\n\\text{PPV} = \\frac{0.09}{0.135}\n$$\nThe exact value is $\\frac{90}{135} = \\frac{2}{3}$. As a decimal, this is $0.6666...$.\nRounding to four significant figures as required, we get $0.6667$.\n\n### Clinical Interpretation\n\nA Positive Predictive Value of $0.6667$ means that for any individual in this population who receives a positive screening test result, there is a $66.67\\%$ probability that they actually have the disease. Conversely, there is a $33.33\\%$ probability that the result is a false positive ($\\Pr(\\neg D | T^+) = 1 - \\text{PPV} \\approx 0.3333$).\n\nWithin the biomedical model, which is concerned with the objective identification and management of biological pathology, this result has critical implications:\n1.  **For clinical decision-making**: The test is useful for screening but is not definitive for diagnosis. A PPV of $0.6667$ is significantly higher than the baseline prevalence of $0.10$, indicating that a positive test substantially increases the likelihood of disease. However, since one-third of positive results are incorrect, a positive screening test result is insufficient grounds for initiating potentially harmful or costly treatments. It serves as a strong indication for further, more accurate (and often more invasive or expensive) confirmatory diagnostic testing.\n2.  **For patient communication**: It is imperative to communicate this probabilistic nature of the test result to the patient. A practitioner must clearly explain that a positive result is not a diagnosis but an indicator that further investigation is warranted. This manages patient anxiety and ensures informed consent for subsequent diagnostic procedures. The focus is on the objective probability of a biological state, aligning with the principles of the biomedical model.",
            "answer": "$$\n\\boxed{0.6667}\n$$"
        },
        {
            "introduction": "This final, advanced practice challenges us to critically evaluate the broader consequences of applying the biomedical model in large-scale screening programs. Using a detailed hypothetical scenario, you will explore the complex and often counterintuitive phenomena of overdiagnosis and overtreatment. This exercise demonstrates that simply detecting more \"disease\" does not automatically translate to better health outcomes, forcing a consideration of patient-relevant metrics like quality of life and all-cause mortality . Engaging with this problem will provide a sophisticated understanding of the limitations of a purely detection-focused model and highlight why a critical perspective on medical interventions is vital.",
            "id": "4750297",
            "problem": "An advanced-undergraduate student in medical psychology is asked to reason about screening within the Biomedical Model of Health and Illness, which conceptualizes disease primarily as biological pathology and evaluates interventions by measurable patient-relevant outcomes. Consider a hypothetical annual screening program for a thyroid microcarcinoma in a population of $N=100{,}000$ adults. The natural history is heterogeneous: a fraction of lesions are progressive (would cause symptoms and disease-specific death if untreated within the patient’s lifetime) and a larger fraction are indolent (would neither cause symptoms nor death within the patient’s lifetime). The program uses a single test with sensitivity $Se=0.90$ and specificity $Sp=0.95$ for both lesion types. Annual incidence rates are $I_{p}=1/1000$ for progressive lesions and $I_{i}=9/1000$ for indolent lesions. All screen-positive patients undergo diagnostic work-up; those with confirmed disease receive surgical treatment. For progressive disease detected by screening, early treatment has no demonstrated reduction in disease-specific mortality compared to usual care after clinical presentation (relative risk reduction $RRR=0$), so the disease-specific mortality remains $m_{p}=0.10$ among progressive cases regardless of screening. Treatment has harms: per treated patient, the probability of a fatal complication is $d_{t}=0.002$ and the expected Quality-Adjusted Life Year (QALY) loss due to non-fatal complications is $q_{t}=0.01$. False positives undergo biopsy with expected QALY loss $q_{FP}=0.01$ and probability of fatal complication $d_{FP}=0.0002$. Patient-relevant outcomes are defined as all-cause mortality and QALYs. There is no material psychosocial benefit from labeling alone.\n\nFrom first principles, use the core definitions of sensitivity $Se$, specificity $Sp$, incidence $I$, disease-specific mortality $m_{p}$, and the epidemiologic concepts of length bias and lead-time bias (appearances of improved survival due to earlier diagnosis without delaying time of death) to reason about the consequences of this screening program. Which option correctly defines overdiagnosis and overtreatment and explains how they arise in programs where detection of indolent disease does not improve patient-relevant outcomes, including the expected directionality of key population metrics?\n\nA. Overdiagnosis is the detection of a “disease” that would not become symptomatic or cause death within the patient’s lifetime, and overtreatment is the causal downstream treatment of such overdiagnosed cases that confers no benefit but imposes harm. In this program, $I_{i}\\gg I_{p}$ and $Se=0.90$, so most true positives are indolent. Expected diagnoses per year increase by approximately $N\\cdot(I_{p}+I_{i})=100{,}000\\cdot(0.001+0.009)=1{,}000$, with about $0.90\\cdot1{,}000=900$ true positives, of which only $0.10$ are progressive. Disease-specific mortality remains approximately $100\\cdot m_{p}=10$ both with and without screening because $RRR=0$. All-cause mortality increases due to procedure-related deaths among treated true positives $\\approx 900\\cdot d_{t}=1.8$ and false positives $\\approx 4{,}950\\cdot d_{FP}\\approx 0.99$, and QALYs decrease by complications among treated true positives $\\approx 900\\cdot q_{t}=9$ plus false positives $\\approx 4{,}950\\cdot q_{FP}=49.5$. Length bias and lead-time bias make survival time from diagnosis appear longer without delaying time of death, thus increasing incidence and time-lived-with-diagnosis without improving patient-relevant outcomes.\n\nB. Overdiagnosis is identical to false positives, and overtreatment is treating false positives. Because $Sp=0.95$, overdiagnosis is negligible, and increased detection necessarily lowers disease-specific mortality; thus, $PPV\\approx 0.95$ and screening reduces all-cause mortality.\n\nC. Overdiagnosis is detecting aggressive disease earlier, and overtreatment is administering more aggressive therapy that reduces disease-specific mortality; because $Se=0.90$, disease-specific mortality must decline in proportion to the increase in incidence, so all-cause mortality and QALYs improve.\n\nD. Overdiagnosis results from low sensitivity $Se$, and overtreatment arises only when complication rates are very high; five-year survival necessarily increases with screening and reflects true patient benefit even when all-cause mortality does not change, so unchanged mortality cannot indicate harm from screening.\n\nSelect the single best option.",
            "solution": "The problem statement is subjected to validation prior to any attempt at a solution.\n\n### Step 1: Extract Givens\n- Population size: $N=100{,}000$ adults.\n- Disease: Thyroid microcarcinoma with two subtypes.\n- Progressive lesions incidence: $I_{p}=1/1000 = 0.001$.\n- Indolent lesions incidence: $I_{i}=9/1000 = 0.009$.\n- Screening test sensitivity: $Se=0.90$.\n- Screening test specificity: $Sp=0.95$.\n- Treatment for progressive disease: Relative risk reduction $RRR=0$.\n- Disease-specific mortality for progressive cases: $m_{p}=0.10$.\n- Treatment-related fatal complication probability: $d_{t}=0.002$.\n- Treatment-related non-fatal QALY loss: $q_{t}=0.01$.\n- False-positive work-up fatal complication probability: $d_{FP}=0.0002$.\n- False-positive work-up QALY loss: $q_{FP}=0.01$.\n- Patient-relevant outcomes: All-cause mortality and Quality-Adjusted Life Years (QALYs).\n- Foundational concepts: Sensitivity ($Se$), specificity ($Sp$), incidence ($I$), disease-specific mortality ($m_p$), length bias, lead-time bias.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded, well-posed, and objective. It provides a hypothetical but plausible scenario based on standard epidemiological and medical concepts such as screening test characteristics ($Se$, $Sp$), disease incidence ($I$), overdiagnosis, overtreatment, patient-relevant outcomes (mortality, QALYs), and statistical biases (length and lead-time). All provided data are numerically consistent and sufficient for a quantitative analysis of the screening program's net effect. The problem does not violate any scientific principles and is free of the invalidating flaws listed in the instructions.\n\n### Step 3: Verdict and Action\nThe problem statement is valid. A full derivation and evaluation of options will be performed.\n\n### Derivation from First Principles\nWe analyze the effects of one year of screening on the population of $N=100{,}000$.\n\n1.  **Population Stratification**:\n    - Number of individuals developing progressive disease in one year: $N_{p} = N \\cdot I_{p} = 100{,}000 \\cdot 0.001 = 100$.\n    - Number of individuals developing indolent disease in one year: $N_{i} = N \\cdot I_{i} = 100{,}000 \\cdot 0.009 = 900$.\n    - Total individuals with new disease (prevalence for screening purposes): $N_{D} = N_{p} + N_{i} = 100 + 900 = 1{,}000$.\n    - Number of individuals without disease (healthy): $N_{H} = N - N_{D} = 100{,}000 - 1{,}000 = 99{,}000$.\n\n2.  **Screening Test Outcomes**:\n    - **True Positives (TP)**: Diseased individuals testing positive.\n    $TP = N_{D} \\cdot Se = 1{,}000 \\cdot 0.90 = 900$.\n    These are composed of:\n    - Progressive cases detected: $TP_{p} = N_{p} \\cdot Se = 100 \\cdot 0.90 = 90$.\n    - Indolent cases detected: $TP_{i} = N_{i} \\cdot Se = 900 \\cdot 0.90 = 810$.\n    \n    - **False Negatives (FN)**: Diseased individuals testing negative.\n    $FN = N_{D} \\cdot (1 - Se) = 1{,}000 \\cdot (1 - 0.90) = 100$.\n\n    - **False Positives (FP)**: Healthy individuals testing positive.\n    $FP = N_{H} \\cdot (1 - Sp) = 99{,}000 \\cdot (1 - 0.95) = 99{,}000 \\cdot 0.05 = 4{,}950$.\n    \n    - **True Negatives (TN)**: Healthy individuals testing negative.\n    $TN = N_{H} \\cdot Sp = 99{,}000 \\cdot 0.95 = 94{,}050$.\n\n3.  **Core Concepts Analysis**:\n    - **Overdiagnosis**: This is the detection of a condition (true pathology) that would never have caused symptoms or death. In this problem, these are the detected indolent cases.\n    Number of overdiagnosed cases = $TP_{i} = 810$.\n    - **Overtreatment**: This is the treatment of overdiagnosed cases. Since all confirmed cases are treated, the number of overtreated individuals is $810$. These individuals are subjected to the harms of treatment for no benefit.\n\n4.  **Impact on All-Cause Mortality**:\n    - **Baseline (No Screening)**: The only deaths attributable to the disease are from the progressive cases. Disease-specific deaths = $N_{p} \\cdot m_{p} = 100 \\cdot 0.10 = 10$. There are no iatrogenic deaths from screening or treatment.\n    - **With Screening**:\n        - Disease-specific deaths: The problem states $RRR=0$, so early detection and treatment do not alter the course of progressive disease. The number of deaths from the disease itself remains $10$.\n        - Iatrogenic deaths from treatment: All true positives ($TP = 900$) are treated. Deaths = $TP \\cdot d_{t} = 900 \\cdot 0.002 = 1.8$.\n        - Iatrogenic deaths from diagnostic work-up: All false positives ($FP = 4{,}950$) undergo biopsy. Deaths = $FP \\cdot d_{FP} = 4{,}950 \\cdot 0.0002 = 0.99$.\n        - Total deaths with screening = $10 (\\text{disease}) + 1.8 (\\text{treatment}) + 0.99 (\\text{biopsy}) = 12.79$.\n    - **Conclusion on Mortality**: The screening program increases the annual all-cause mortality in the population by $2.79$ deaths.\n\n5.  **Impact on QALYs**:\n    - **Baseline (No Screening)**: No QALY loss from screening procedures. We consider the baseline change to be $0$.\n    - **With Screening**:\n        - QALY loss from treatment complications: Affects all treated patients ($TP = 900$). Loss = $TP \\cdot q_{t} = 900 \\cdot 0.01 = 9$ QALYs.\n        - QALY loss from false-positive work-up: Affects all false positives ($FP = 4{,}950$). Loss = $FP \\cdot q_{FP} = 4{,}950 \\cdot 0.01 = 49.5$ QALYs.\n        - Total QALY loss = $9 + 49.5 = 58.5$.\n    - **Conclusion on QALYs**: The screening program results in a net loss of $58.5$ QALYs per year for the population.\n\n6.  **Role of Biases**:\n    - **Length Bias**: The screening test is inherently more likely to find slow-growing, indolent lesions because they are present in a detectable, preclinical state for a longer duration than aggressive lesions. The problem models this directly by setting $I_{i} \\gg I_{p}$.\n    - **Lead-Time Bias**: For the $90$ progressive cases detected early, screening advances the time of diagnosis but does not delay the time of death (since $RRR=0$). This artificially inflates survival time measured from diagnosis, creating a misleading appearance of benefit where none exists.\n\n### Option-by-Option Analysis\n\n**A. Overdiagnosis is the detection of a “disease” that would not become symptomatic or cause death within the patient’s lifetime, and overtreatment is the causal downstream treatment of such overdiagnosed cases that confers no benefit but imposes harm. In this program, $I_{i}\\gg I_{p}$ and $Se=0.90$, so most true positives are indolent. Expected diagnoses per year increase by approximately $N\\cdot(I_{p}+I_{i})=100{,}000\\cdot(0.001+0.009)=1{,}000$, with about $0.90\\cdot1{,}000=900$ true positives, of which only $0.10$ are progressive. Disease-specific mortality remains approximately $100\\cdot m_{p}=10$ both with and without screening because $RRR=0$. All-cause mortality increases due to procedure-related deaths among treated true positives $\\approx 900\\cdot d_{t}=1.8$ and false positives $\\approx 4{,}950\\cdot d_{FP}\\approx 0.99$, and QALYs decrease by complications among treated true positives $\\approx 900\\cdot q_{t}=9$ plus false positives $\\approx 4{,}950\\cdot q_{FP}=49.5$. Length bias and lead-time bias make survival time from diagnosis appear longer without delaying time of death, thus increasing incidence and time-lived-with-diagnosis without improving patient-relevant outcomes.**\n- The definitions of overdiagnosis and overtreatment are correct.\n- The analysis of the composition of true positives is correct ($TP_i=810$, $TP_p=90$, so $90\\%$ are indolent).\n- The quantitative estimates are correct: total incident cases are $1{,}000$, detected TPs are $900$.\n- The proportion of progressive cases among TPs is $90/900 = 0.10$, which is correct.\n- The calculation and conclusion regarding unchanged disease-specific mortality are correct.\n- The calculations of iatrogenic deaths ($1.8$ and $0.99$) and the conclusion that all-cause mortality increases are correct.\n- The calculations of QALY losses ($9$ and $49.5$) and the conclusion that population QALYs decrease are correct.\n- The explanation of length and lead-time bias is accurate and relevant.\nThis option provides a complete, quantitatively accurate, and conceptually sound analysis of the problem.\n**Verdict**: **Correct**.\n\n**B. Overdiagnosis is identical to false positives, and overtreatment is treating false positives. Because $Sp=0.95$, overdiagnosis is negligible, and increased detection necessarily lowers disease-specific mortality; thus, $PPV\\approx 0.95$ and screening reduces all-cause mortality.**\n- The definition \"Overdiagnosis is identical to false positives\" is fundamentally incorrect. Overdiagnosis concerns true positives for an indolent disease. False positives are disease-free individuals.\n- The claim that increased detection necessarily lowers disease-specific mortality is false and contradicts the given $RRR=0$.\n- The calculation of Positive Predictive Value ($PPV$) is incorrect. $PPV = TP/(TP+FP) = 900/(900+4,950) = 900/5,850 \\approx 0.154$, not $\\approx 0.95$. The option confuses PPV with specificity.\n- The conclusion that screening reduces all-cause mortality is the opposite of the derived result.\n**Verdict**: **Incorrect**.\n\n**C. Overdiagnosis is detecting aggressive disease earlier, and overtreatment is administering more aggressive therapy that reduces disease-specific mortality; because $Se=0.90$, disease-specific mortality must decline in proportion to the increase in incidence, so all-cause mortality and QALYs improve.**\n- The definition \"Overdiagnosis is detecting aggressive disease earlier\" is incorrect. This is the goal of beneficial screening, not overdiagnosis. Overdiagnosis is detecting indolent disease.\n- The claim that disease-specific mortality must decline because $Se=0.90$ is false; benefit depends on effective treatment for early-stage disease, which is absent here ($RRR=0$).\n- The conclusion that all-cause mortality and QALYs improve is the opposite of the derived result.\n**Verdict**: **Incorrect**.\n\n**D. Overdiagnosis results from low sensitivity $Se$, and overtreatment arises only when complication rates are very high; five-year survival necessarily increases with screening and reflects true patient benefit even when all-cause mortality does not change, so unchanged mortality cannot indicate harm from screening.**\n- The claim that overdiagnosis results from low sensitivity is incorrect. Overdiagnosis is driven by the detection of indolent disease, often facilitated by high sensitivity. Low sensitivity would cause underdiagnosis.\n- The claim that overtreatment arises \"only\" when complication rates are high is incorrect. Overtreatment is defined by the absence of benefit, making any level of harm a net negative.\n- The assertion that increased five-year survival reflects \"true patient benefit\" is a classic fallacy. It ignores the confounding effects of lead-time and length biases. All-cause mortality is the superior metric for true benefit, and here it actually worsens, indicating definite harm.\n**Verdict**: **Incorrect**.",
            "answer": "$$\\boxed{A}$$"
        }
    ]
}